TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EQL Pharma AB ( (SE:EQL) ) just unveiled an announcement.
EQL Pharma AB announced that delivery delays from several suppliers have impacted their second-quarter sales, resulting in a weaker than expected financial performance for the 2025/26 fiscal year. The company anticipates full-year growth closer to 15% rather than the previously expected 30%, with sales in Q2 showing only single-digit growth. Despite these temporary setbacks, EQL Pharma maintains confidence in achieving its five-year targets.
More about EQL Pharma AB
EQL Pharma AB specializes in developing and selling generic drugs that are medically equivalent to original drugs. The company focuses on niche generics with limited competition and operates primarily in the Nordic and European markets. EQL Pharma is listed on the Nasdaq Stockholm stock market and collaborates with leading manufacturers in the EU and Asia.
YTD Price Performance: -1.98%
Average Trading Volume: 32,078
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.34B
Learn more about EQL stock on TipRanks’ Stock Analysis page.